Group 1 - The core point of the article is that Kanghui Pharmaceutical has completed adjustments related to corporate governance as outlined in the supplementary agreement of the share transfer agreement [1] - Kanghui Holdings voluntarily relinquishes its voting rights corresponding to 10% of the shares held in Kanghui Pharmaceutical, resulting in a change of the controlling shareholder to Yuehe Zhichuang [1] - The actual controllers of the company have changed to Li Hongming and Wang Xuefang, a couple [1]

Core Viewpoint - Kanghui Pharmaceutical (603139.SH) is facing intensified market competition and declining product sales margins due to adverse industry conditions, leading to operational adjustments and production halts at its subsidiary Shaanxi Youbang [1] Company Summary - Kanghui Pharmaceutical's product sales gross margin has been continuously declining as a result of increased market competition [1] - Shaanxi Youbang plans to adjust its product offerings and has attempted to trial production of multiple new products; however, these efforts have been unsuccessful due to issues with production processes, equipment updates, and immature technology [1] - To mitigate further losses and protect shareholder interests, Shaanxi Youbang has decided to fully suspend production at workshops 1, 2, and 3, with future production resumption contingent on market conditions [1]

陕西康惠制药股份有限公司 关于控股子公司停产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为了减少亏损，维护股东利益，陕西康惠制药股份有限公司（以下简称"公 司"）的控股子公司陕西友帮生物医药科技有限公司（以下简称"陕西友帮"）已 于近日停产，后续将根据市场情况决定是否恢复生产。现将有关情况公告如下： 证券代码：603139 证券简称：康惠制药 公告编号：2025-057 陕西友帮系公司控股子公司，其主要生产化药中间体，近年来连续亏损，本 次停产预计有利于公司避免后续进一步亏损，减少其对公司业绩的影响，避免继 续生产造成更大规模的亏损和资金投入，有利于降低运营成本，契合公司战略发 展方向，符合公司和全体股东的利益；此外，本次停产预计将可能对相关主体关 于陕西友帮的业绩承诺完成情况造成一定影响；本次停产对公司经营数据的具体 影响以经审计的财务报告为准。 一、本次停产原因 受行业大环境影响，公司产品市场竞争加剧，产品销售毛利持续下降，陕西 友帮拟调整其他产品，更换多个产品试生产，但因产品工艺、设备更新、技术不 成熟等原因 ...

证券代码：603139 证券简称：康惠制药 公告编号：2025-054 陕西康惠制药股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 4 日 (二)股东大会召开的地点：咸阳市秦都区胭脂路 36 号公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 104 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 44,758,537 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | 44.8123 | | 总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，以现场和网络投票相结合的方式召开，现 场会议由公司董事长王延岭先生主持。本次股东大会的召集、召开和决策程序， 符合《 ...

致：陕西康惠制药股份有限公司 北京市金杜律师事务所上海分所关于 陕西康惠制药股份有限公司 2025 年第二次临时股东大会 之法律意见书 北京市金杜律师事务所上海分所（以下简称本所）接受陕西康惠制药股份有 限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证券 法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委员 会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国境内（以 下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政区、中国澳 门特别行政区和中国台湾省）现行有效的法律、行政法规、规章和规范性文件和 现行有效的《陕西康惠制药股份有限公司章程》（以下简称《公司章程》）有关规 定，指派律师出席并见证公司于 2025 年 9 月 4 日召开的 2025 年第二次临时股东 大会（以下简称本次股东大会），并就本次股东大会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2021 年年度股东大会审议批准的《公司章程》； 2. 公司 2025 年 8 月 20 日刊登于巨潮资讯网、《中国证券报 ...

证券代码：603139 证券简称：康惠制药 公告编号：2025-055 陕西康惠制药股份有限公司 第六届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 陕西康惠制药股份有限公司（以下简称"公司"）于 2025 年 9 月 4 日召开 2025 年第二次临时股东大会，选举产生了第六届董事会成员。为保证公司董事 会顺利运行，经全体董事同意后，豁免会议通知时间要求，现场决定召开公司第 六届董事会第一次会议。会议应出席董事 9 人，实际参加董事 9 人。本次会议由 全体董事推举的董事李红明先生主持。本次会议符合《公司法》、《公司章程》和 《董事会议事规则》的有关规定，会议的召集、召开合法有效。 二、董事会会议审议情况 经与会董事审议和表决，通过了以下决议： 2、审议通过《关于选举公司第六届董事会专门委员会委员的议案》 本次会议选举第六届董事会各专门委员会委员，任期与第六届董事会一致， 自本次董事会审议通过之日起三年。公司董事会下设战略委员会、审计委员会、 提名委员会及薪酬与考核委员会， ...

Core Viewpoint - Kanghui Pharmaceutical (603139.SH) is facing intensified market competition and declining product sales margins, leading to operational adjustments and production halts at its subsidiary Shaanxi Youbang [1][2] Group 1: Company Operations - Shaanxi Youbang, a subsidiary of the company, is experiencing continuous losses due to product adjustments and production challenges, prompting a decision to halt production in workshops 1, 2, and 3 [1] - The halt in production is expected to mitigate further losses and reduce operational costs, aligning with the company's strategic development direction [1] Group 2: Financial Impact - In 2024, Shaanxi Youbang's total assets are projected to account for 16.91% of the company's most recent audited total assets, with its revenue contributing 1.42% to the consolidated revenue [2] - The projected net loss for Shaanxi Youbang in 2024 is estimated at 52.51 million yuan, impacting the company's net profit by 26.78 million yuan, which represents 29.88% of the company's net profit attributable to shareholders [2]

人民财讯9月4日电，康惠制药（603139）9月4日晚间公告，为了减少亏损，维护股东利益，公司控股子 公司陕西友帮生物医药科技有限公司(简称"陕西友帮")已于近日停产，后续将根据市场情况决定是否恢 复生产。此次停产预计将可能对相关主体关于陕西友帮的业绩承诺完成情况造成一定影响。 ...

Core Viewpoint - Kanghui Pharmaceutical (603139.SH) is facing intensified market competition and declining product sales margins, leading to operational adjustments and production halts at its subsidiary Shaanxi Youbang to mitigate losses and protect shareholder interests [1][2] Group 1: Company Operations - Shaanxi Youbang, a subsidiary of Kanghui Pharmaceutical, is experiencing continuous losses and has decided to halt production in workshops 1, 2, and 3 due to unsuccessful product adjustments and production challenges [1] - The halt in production is expected to help the company avoid further losses and reduce operational costs, aligning with the company's strategic development direction [1] Group 2: Financial Impact - In 2024, Shaanxi Youbang's total assets accounted for 16.91% of the company's most recent audited total assets, while its revenue represented 1.42% of the consolidated revenue [2] - The net profit for Shaanxi Youbang in 2024 is projected to be -52.51 million, impacting the company's audited net profit attributable to shareholders by -26.78 million, which constitutes 29.88% of the total [2]

Market Overview - The Chinese traditional medicine sector experienced a decline of 0.82% on September 4, with ST Xiangxue leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the traditional medicine sector included: - Wanbangde (002082) with a closing price of 9.98, up 3.42% and a trading volume of 487,100 shares, totaling 482 million yuan [1] - Shengtang Pharmaceutical (833266) closed at 11.20, up 2.38% with a trading volume of 39,300 shares, totaling 44.12 million yuan [1] - Significant decliners included: - ST Qingyin (300147) with a closing price of 10.18, down 6.86% and a trading volume of 288,600 shares, totaling 301 million yuan [2] - Weikang Pharmaceutical (300878) closed at 21.42, down 6.83% with a trading volume of 54,300 shares, totaling 118 million yuan [2] Capital Flow - The traditional medicine sector saw a net outflow of 819 million yuan from institutional investors, while retail investors contributed a net inflow of 925 million yuan [2] - The capital flow for specific stocks showed: - Wanbangde (002082) had a net inflow of 30.53 million yuan from institutional investors, while retail investors had a net outflow of 19.38 million yuan [3] - Jianmin Group (600976) experienced a net inflow of 26.19 million yuan from institutional investors, with retail investors seeing a net outflow of 23.73 million yuan [3]